ArticleInfection and immunity2004
Nucleic acid vaccination with Schistosoma mansoni antioxidant enzyme cytosolic superoxide dismutase and the structural protein filamin confers protection against the adult worm stage.
Article in Infection and immunity, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 45 citations in OpenAlex.
- Superoxide Dismutases in Immune Regulation and Infectious Diseases.Antioxidants (Basel, Switzerland) · 2025Review
- Pre-clinical studies of Schistosoma mansoni vaccines: A scoping review.PLoS neglected tropical diseases · 2025Article
- Article
- A comprehensive and critical overview of schistosomiasis vaccine candidates.Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2021Review
- Dynamics of serological responses to defined recombinant proteins during Schistosoma mansoni infection in mice before and after the treatment with praziquantel.PLoS neglected tropical diseases · 2020Article
- Haptoglobin Phenotypes and Susceptibility toMediterranean journal of hematology and infectious diseases · 2017Article
- Specific humoral response of hosts with variable schistosomiasis susceptibility.Immunology and cell biology · 2016Article
- Kicking in the Guts: Schistosoma mansoni Digestive Tract Proteins are Potential Candidates for Vaccine Development.Frontiers in immunology · 2015Review
- Protective Potential of Antioxidant Enzymes as Vaccines for Schistosomiasis in a Non-Human Primate Model.Frontiers in immunology · 2015Article
- Of monkeys and men: immunomic profiling of sera from humans and non-human primates resistant to schistosomiasis reveals novel potential vaccine candidates.Frontiers in immunology · 2015Article
- Immunology of human schistosomiasis.Parasite immunology · 2014Review
- Discovery of novel Schistosoma japonicum antigens using a targeted protein microarray approach.Parasites & vectors · 2014Article
- Use of an Sm-p80-based therapeutic vaccine to kill established adult schistosome parasites in chronically infected baboons.The Journal of infectious diseases · 2014Article
- Interaction Between the Neglected Tropical Disease Human Schistosomiasis and HCV Infection in Egypt: a Puzzling Relationship.Journal of clinical and translational hepatology · 2014Review
- Serological screening of the Schistosoma mansoni adult worm proteome.PLoS neglected tropical diseases · 2014Article
- Vaccination with enzymatically cleaved GPI-anchored proteins from Schistosoma mansoni induces protection against challenge infection.Clinical & developmental immunology · 2012Article
- The redox biology of schistosome parasites and applications for drug development.Current pharmaceutical design · 2012Review
- Computational vaccinology: an important strategy to discover new potential S. mansoni vaccine candidates.Journal of biomedicine & biotechnology · 2011Review
- Functional expression and characterization of a cytosolic copper/zinc-superoxide dismutase of Spirometra erinacei.Parasitology research · 2010Article
- Partial immunity to Fasciola hepatica in mice after vaccination with FhSAP2 delivered as recombinant protein or DNA construct.Ethnicity & disease · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Schistosomiasis remains a worldwide endemic cause of chronic and debilitating illness. There are two paradigms that exist in schistosome immunology. The first is that the schistosomule stages are the most susceptible to immune killing, and the second is that the adult stage, through evolution of defense mechanisms, can survive in the hostile host environment. One mechanism that seems to aid the adult worm in evading immune killing is the expression of antioxidant enzymes to neutralize the effects of reactive oxygen and nitrogen species. Here, we challenge one paradigm by targeting adult Schistosoma mansoni worms for immune elimination in an experimental mouse model using two S. mansoni antioxidants, cytosolic superoxide dismutase (SmCT-SOD) and glutathione peroxidase (SmGPX), and a partial coding sequence for a structural protein, filamin, as DNA vaccine candidates. DNA vaccination with SmCT-SOD induced a mean of 39% protection, filamin induced a mean of 50% protection, and SmGPX induced no protection compared to controls following challenge with adult worms by surgical transfer. B- and T-cell responses were analyzed in an attempt to define the protective immune mechanism(s) involved in adult worm killing. SmCT-SOD-immunized mice presented with a T1 response, and filamin-immunized mice showed a mixed T1-T2 response. We provide evidence for natural boosting after vaccination. Our results demonstrate that adult worms can be targeted for immune elimination through vaccination. This represents an advance in schistosome vaccinology and allows for the development of a therapeutic as well as a prophylactic vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.